|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Green wireless communications via cog- nitive dimension: an overview 显示文摘 | Gur G Alagoz F | 2011 | Network IEEE2011，25，2： | 1 |
| 2 | Green wireless conununications via cognitive dimension: an overview 显示文摘 | Gur G Alagoz F | 2011 | Network IEEE2011，25，2： | 1 |
| 3 | Cognitive femtocell net- works: An overlay architecture for localized dynamic spectrum access显示文摘 | Gur G Bayhan S Alagoz F | 2010 | IEEE Wireless Communications2010，17，4： | 1 |
| 4 | Cognitive Femtocell Networks: An Overlay Architecture for Localized Dynamic Spectrum Access显示文摘 | GOR G BAYHAN S AlAGOZ F et at | 2010 | IEEE Wireless Communications2010，17，4： | 1 |
| 5 | Lcamitine in experimental retinal ischemia -- reperfusion injury 显示文摘 | Alagoz G Celiker U llhan N | 2002 | Ophthalmologica2002，216，2： | 1 |
| 6 | Green wireless communication via cognitive dimension:an overview显示文摘 | Gur G Alagoz F | 2011 | IEEE Network2011，25，2： | 1 |
| 7 | Green wireless communications via cognitive dimension: an overview 显示文摘 | Gur G Alagoz F | 2011 | IEEE Network2011，25，2： | 1 |
| 8 | Comparison of two different treatment regimens’ efficacy in neovascular age-related macular degeneration in Turkish population—based on real life data-Bosphorus RWE Study Group显示文摘AIM: To compare two different anti-vascular endothelial growth factor(anti-VEGF) treatment regimens'-a priori pro re nata(PRN) and PRN regimen following^(th)e loading phaseanatomical and functional results in neovascular agerelated macular degeneration(n AMD) patients. METHODS: Totally 544 n AMD patients followed and treated with aflibercept(n=135) and ranibizumab(n=409)at 9 different centers between 2013 and 2015 were enrolled into^(th)is retrospective multicenter study. Patients with initial best corrected visual acuity(BCVA) interval of 1.3-0.3(log MAR) and a minimum follow-up of 12 mo were included. Patients under two different regimens-a priori pro re nata(1+PRN) or 3 consecutive intravitreal injections followed by a PRN regimen(3+PRN)-were compared in BCVA at 3^(th), 6^(th) and 12^(th) months, and in central macular^(th)ickness(CMT) at 6^(th) and 12^(th) months. The total study group, intravitreal ranibizumab(IVR) and intravitreal aflibercept(IVA) groups were evaluated separately. RESULTS: The mean CMT decreased in^(th)e 1+PRN(n=101) regimen from 407 to 358 and 340 μm and in^(th)e 3+PRN(n=443) group from 398 to 318 and finally to 310 μm at months 6 and 12, respectively. Anatomically,^(th)e CMT reduction at 6^(th) month(48.5 vs 76.4;P<0.05) was statistically significant in favor of 3+PRN group. BCVA changed in 1+PRN group from 0.77 to 0.78, 0.75 and 0.75;in 3+PRN group from 0.81 to 0.69, 0.72, and 0.76 at months 3, 6, and 12, respectively. Visual gain was statistically better in 3+PRN group at 3^(th) month(-0.01 vs 0.12;P<0.001). In IVR group, CMT reduction was in greater in 3+PRN at 6^(th)(44 vs 72) and 12^(th) month(61 vs 84), but statistically insignificant. The 3+PRN group revealed statistically better visual results at 3^(th) month(-0.02 vs 0.11, P<0.05). In IVA group, although statistically insignificant, CMT reduction(61 vs 89, 6^(th) month;85 vs 97, 12^(th) month) and visual gain(0.02 vs 0.16;0.02 vs 0.14;0.05 vs 0.11) was found in favor of 3+PRN group at all visits.CONCLUSION: The loading dose of anti-VEGF treatments in n AMD leads to significantly better anatomical and functional results, regardless of the agent, specially in early follow-up interval. | Burak Erden Selim Bolükbasi Abdullah Ozkaya Levent Karabas Cengiz Alagoz Zeynep Alkin Ozgür Artunay Sadik Etka Bayramoglu Gokhan Demir Mehmet Demir Ali Demircan Gürkan Erdogan Mehmet Erdogan Erdem Eris Havva Kaldirim Ismail Umut Onur Ozen Ayranci Osmanbasoglu Sezin Ozdogan Erkul Mine Oztürk Irfan Perente Kübra Sarici Nihat Sayin Dilek Yasa Ihsan Yilmaz Zeynep Yilmazabdurrahmanoglu 无 | 2020 | International Journal of Ophthalmology(English edition)2020，13，1： | 1 |
| 9 | lntracarneal inlay to correct presbyopia: Long-term results显示文摘 | Yilmaz OF Alagoz N Pekel G | 2011 | J Cataract Refract Surg2011，37，7： | 1 |
| 10 | Energy efficiency and satellite networking: A holistic overview 显示文摘 | Alagoz F Gur G | 2011 | Proceedings of the IEEE2011，99，11： | 1 |
| 11 | Cognitive femtocell net- works: an overlay architecture for localized dynamic spectrum access 显示文摘 | Gur G Bayhan S Alagoz F | 2010 | IEEE Wireless Communications2010，17，8： | 1 |
| 12 | Green wireless communications via cog- nitive dimension : an overview 显示文摘 | Gur G Alagoz F | 2011 | IEEE Network2011，25，2： | 1 |
| 13 | A spectrum-aware clustering for efficient multimediarouting in cognitive radio sensor networks显示文摘 | Shah G A Alagoz F Fadel E A | 2014 | Vehicular Technology IEEE Transactions on2014，63，7： | 1 |
| 14 | A comparative study of bimatoprost and travoprost:effect on intraocular pressure and ocular circulation in newly diagnosed glaucoma patients显示文摘 | Gurel K Bayer A | 2008 | Ophthalmologica2008，222，2： | 1 |
| 15 | 玻璃体腔注射bevacizumab治疗视网膜分支静脉阻塞继发黄斑水肿(英文)显示文摘目的:通过测量随访12mo后的中央黄斑厚度(CMT)和视力,评估玻璃体腔注射bevacizumab治疗视网膜分支静脉阻塞(BRVO)继发黄斑水肿(ME)的效果。方法:被诊断为BRVO继发ME的患者行眼科检查、CMT测量、荧光素血管造影。排除荧光素血管造影出现黄斑缺血患者,其他疾病继发的其他部位新生血管化患者,有眼内治疗史(激光治疗、玻璃体腔注射或眼科手术)患者。CMT 〉250μm的32例患者给予bevacizumab(Altuzan,0.125mg/0.05mL)注射治疗,并随访12mo。分析最佳矫正视力(BCVA)logMAR数据和CMT控制参数。使用Minitab15.0软件统计分析配对t检验,P〈0.05有统计学意义。结果: BCVA logMAR数据和CMT控制参数的平均值较注射前有明显改变(P〈0.01)。平均最佳矫正视力增量为0.477±0.235,平均CMT较注射前下降257.906±88.865。10例(31%)患者对单次注射有阳性反应,平均12.6±0.66mo未复发ME。5例(15.6%)患者接受两次注射,17例(53%)3次以上。单眼平均注射量2.18±0.91(1~4)。第一组ME复发时间为2.45±0.63mo,第二组为2.58±0.66mo,第三组为3.17±0.48mo。5例(15.6%)患者需要多次注射以减轻ME,视力并未随ME的减轻而增加。结论:玻璃体腔注射bevacizumab是常规治疗BRVO继发ME的方法,有效、快速、安全。为了使疗效持久,需加强后续处理,通过激光或长效药物保持无水肿状态。视网膜静脉循环和ME须通过荧光素血管造影观察,而不能采取频繁注射。是否需再次注射必须根据ME的临床表现和视力的预测来判断。 | Seref Istek Ozlem Bursall Gürsoy Alagoz | 2014 | 国际眼科杂志2014，14，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员